A Phase 1, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived from Mobilized Peripheral Blood (Orcagraft) With Single Agent Graft-Versus-Host Disease Prophylaxis, In Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Protocol No
ORCA-GRAFT-OGFT001-001
Principal Investigator
Sameem Abedin
Phase
I
Summary
To find out more about a new type of blood stem cell transplant, OrcaGraft, in people with blood cancers and myelodysplastic syndromes.
Description
Study of Engineered Donor Grafts (OrcaGraft) in Recipients Undergoing Allogenic BMT for Heme Malignancies
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: